Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses
Year: 2017
Type: conference-abstract
Source: Cancer Research
Institutions: Queen Mary University of London, Barts Cancer Institute, Vall d'Hebron Hospital Universitari, Comprehensive Cancer Centers of Nevada, Yale University, Dana-Farber Cancer Institute, Massachusetts General Hospital, University of Chicago Medical Center, Angeles Clinic and Research Institute, Centre Léon Bérard, Institut Claudius Regaud, Pinnacle Oncology Hematology, Annexon Biosciences (United States), Instacart (United States), Johns Hopkins University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: atezolizumab, metastatic triple-negative breast cancer, PD-L1 expression, tumor-infiltrating lymphocytes, immune checkpoint inhibitors, long-term clinical outcomes, objective response rate, overall survival, biomarker analysis, CD8+ T cells, tumor-associated macrophages, treatment safety, nivolumab, pembrolizumab
Open Access status: closed
OpenAlex ID: W2740705517
